文献速递MDS 与骨髓增殖性肿瘤

JUMP 3b 期扩大可及研究:芦可替尼治疗骨髓纤维化的主要分析

Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
PubMed 文献 · Br J Haematol · 2020-02-04

JUMP 是一项纳入 2233 例骨髓纤维化患者的 3b 期扩大可及研究,评估芦可替尼安全性及疗效,包括血小板<100×10^9/L 及无脾肿大患者。最常见不良事件为贫血和血小板减少,但很少导致停药;低血小板队列血小板减少恶化率更高。芦可替尼使脾长及症状有临床意义的改善,安全性与此前报道一致,支持用于血小板 50-100×10^9/L 患者。

要点

  • 芦可替尼使脾长和症状有临床意义改善,包括低血小板及无脾肿大患者。

核心结论

  • 芦可替尼在骨髓纤维化患者中安全性与此前报道一致,未发现新的安全性问题。
  • 研究支持芦可替尼用于血小板计数 50-100×10^9/L 的患者。

研究设计与样本

  • JUMP 是一项 3b 期扩大可及研究,纳入 2233 例骨髓纤维化患者。
  • 研究在临床试验外无法获得芦可替尼的国家开展,纳入血小板<100×10^9/L 及无脾肿大患者。

主要发现

  • 非血液学不良事件(包括感染)主要为 1/2 级。
  • 芦可替尼使脾长和症状有临床意义改善,包括低血小板患者;无脾肿大患者症状亦改善。

临床怎么用

  • 芦可替尼可用于骨髓纤维化患者,包括血小板 50-100×10^9/L 者,需监测贫血和血小板减少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ruxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor approved for the treatment of myelofibrosis (MF). Ruxolitinib was assessed in JUMP, a large (N = 2233), phase 3b, expanded-access study in MF in countries without access to ruxolitinib outside a clinical trial, which included patients with low platelet counts (<100 × 109 /l) and patients without splenomegaly - populations that have not been extensively studied. The most common adverse events (AEs) were anaemia and thrombocytopenia, but they rarely led to discontinuation (overall, 5·4%; low-platelet cohort, 12·3%). As expected, rates of worsening thrombocytopenia were higher in the low-platelet cohort (all grades, 73·2% vs. 53·5% overall); rates of anaemia were similar (all grades, 52·9% vs. 59·5%). Non-haematologic AEs, including infections, were mainly grade 1/2. Overall, ruxolitinib led to meaningful reductions in spleen length and symptoms, including in patients with low platelet counts, and symptom improvements in patients without splenomegaly. In this trial, the largest study of ruxolitinib in patients with MF to date, the safety profile was consistent with previous reports, with no new safety concerns identified. This study confirms findings from the COMFORT studies and supports the use of ruxolitinib in patients with platelet counts of 50-100 × 109 /l. (ClinicalTrials.gov identifier NCT01493414).

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Al-Ali HK, Griesshammer M, Foltz L, et al. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol. 2020. PMID: 32017044. doi:10.1111/bjh.16462

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。